Aplastic Anemia: Pathophysiology and Treatment

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages S119-S125

  Young, Neal S ^a   Bacigalupo, Andrea ^b   Marsh, Judith C W ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antithymocyte globulin; Aplastic anemia; Haemopoietic stem cell transplantation

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; TELOMERASE; THYMOCYTE ANTIBODY;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CHRONIC GRAFT REJECTION; CLONAL EVOLUTION; CORD BLOOD STEM CELL TRANSPLANTATION; GENE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MUTATION; PATHOGENESIS; PATHOPHYSIOLOGY; RELAPSE; TELOMERE HOMEOSTASIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; GENETICS; IMMUNOLOGY; METHODOLOGY; REVIEW;

ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CORD BLOOD STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 77953078209     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.09.013     Document Type: Article

References (31)

1. Fuhrer, M., Risk-adapted procedures for HSCT from alternative donors in children with severe aplastic anemia. Bone Marrow Transplant 42:Suppl 2 (2008), S97–S100.
2. Locasciulli, A., Oneto, Rosi, Bacigalupo, Andrea, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 92 (2007), 11–18.
3. Yoshimi, A., Kojima, S., Taniguchi, S., et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 14 (2008), 1057–1063.
4. Young, N.S., Calado, R.T., Scheinberg, P., Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108 (2006), 2509–2519.
5. Valdez, J.M., Scheinberg, P., Young, N.S., Walsh, T.J., Infections in patients with aplastic anemia. Semin Hematol, 46, 2009, 269.
6. Maciejewski, J.P., Sloand, E.M., Nunez, O., Boss, C., Young, N.S., Recombinant humanized anti-IL2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 102 (2003), 3584–3586.
7. Scheinberg, P., Wu, C., Nunez, O., Young, N.S., Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 144 (2009), 206–216.
8. Frickhofen, N., Heimpel, H., Kaltwasser, J.P., Schrezenmeier, H., for the German Aplastic Anaemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomised trial comparing treatments of aplastic anemia. Blood 101 (2003), 1236–1242.
9. Socie, G., Mary, Jean-Yves, Schrezenmeier, Hubert, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 109 (2007), 2794–2796.
10. Sloand, E.M., Yong, A.S.M., Ramkissoon, S., et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 103 (2006), 14483–14488.
11. Calado, R.T., Young, N.S., Telomere maintenance and human bone marrow failure. Blood 111 (2008), 4446–4455.
12. Kirwan, M., Dokal, I., Dyskeratois congenita, stem cells, and telomeres. Biochim Biophys Acta 792 (2009), 371–379.
13. Passweg, J.R., Tichelli, A., Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?. Haematologica 94 (2009), 310–312.
14. Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. Published Online: Aug 10 2009.
15. Kao, S.Y., Xu, W., Brandwein, J.M., et al. Outcomes of older patients (≥60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. Br J Haematol 143 (2008), 738–743.
16. Sugimori, C., Chuhjo, T., Feng, X., et al. Minor populations of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107 (2005), 1308–1314.
17. Cooper, J.N., Calado, R., Wu, C., et al. Telomere Length of peripheral blood leukocytes predicts relapse and clonal evolution after immunosuppressive therapy in severe aplastic anemia. Blood, 112, 2008, 442.
18. Gurion, R., Gafter-Gvili, A., Paul, M., et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 94 (2009), 712–719.
19. Scheinberg, P., Nunez, O., Wu, C., Young, N., Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 133 (2006), 606–611.
20. Scheinberg, P., Wu, C.O., Nunez, O., et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 94 (2009), 348–354.
21. Scheinberg, P., Nunez, O., Young, N., Re-treatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 133 (2006), 622–627.
22. Risitano, A.M., Seneca, E., Marando, L., et al. Subcutaneous Alemtuzumab is a safe and effective treatment for global or single-lineage immune-mediated marrow failures: a survey from the EBMT-WPSAA. Blood (ASH Annu Meet Abstr), 112, 2008, 1042.
23. Schrezenmeier, H., Passweg, J.R., Marsh, J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia: a report from the European Group for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research. Blood 110 (2007), 1397–1400.
24. Champlin, R.E., Perez, W.S., Passweg, J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 109 (2007), 4582–4585.
25. George, B., Methews, V., Viswabandya, A., Kavitha, M.L., Srivastava, A., Chandy, M., Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant 40 (2007), 13–18.
26. Horan, J.T., Carreras, J., Tarima, S., et al. Risk factors affecting outcome of second HLA-matched sibling donor transplantations for graft failure in severe acquired aplastic anemia. Biol Blood Marrow Transplant 15 (2009), 626–631.
27. Lawler, M., McCann, S.R., Marsh, J.C., et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol, 144, 2009 933–845.
28. Maury, S., Balere-Appert, M.L., Chir, Z., et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 92 (2007), 589–596.
29. Kojima, S., Matsuyama, T., Kato, S., et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 100 (2002), 799–803.
30. Deeg, H.J., Amylon, I.D., Harris, R.E., et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 7 (2001), 208–215.
31. Ruggeri, A., de Latour, R.P., Rocha, V., et al. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol 143 (2008), 404–408.